Welcome to the e-CCO Library!

P538: The reliability of patient performed fecal calprotectin testing
Year: 2021
Source: ECCO'21 Virtual
Authors: Crouwel, F.(1);Dijkhuis, L.E.J.L.(1);Duijvestein, M.(1);Buiter, H.J.C.(2);De Boer, N.K.(1);Hamer, H.M.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P538: Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Z. Shavit-Brunschwig1, O. Ledder1, G. Focht1, D. Urlep2, R. Lev-Tzion1, D. Marcus1, E. Broide3, A. Assa4, S. Hussey5, A. Yerushalmy-Feler6, A. Levine7, J. Markowitz8, C. Norden9, D. Turner*1

Created: Friday, 22 February 2019, 9:41 AM
P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.R. Lichtenstein1, B. Bressler2, S. Vermeire3, C. Francisconi4, N. Lawendy5, H. Shi5, L. Salese5, D. Judd5, E.V. Loftus Jr6

Created: Thursday, 30 January 2020, 10:12 AM
P539: COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.
Year: 2022
Source: ECCO'22
Authors: Shafrir, A.(1,2);Benson, A.A.(1);Zinger, A.(1);Shauli Aharonov, M.(3);Katz, L.H.(1);
Created: Friday, 11 February 2022, 3:56 PM
P539: Does a change in therapeutic approach modify outcome in IBD patients? A comparison between two cohorts 2004–2007 and 2010–2013
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Viola A.*1, Ferracane C.2, Costantino G.1, Alibrandi A.3, Inserra G.2, Fries W.1

Created: Wednesday, 20 February 2019, 10:36 AM
P539: Impact of a multi-disciplinary team meeting for managing inflammatory bowel disease patients: professional practice analysis based on 869 cases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Del Arco1, P. Rivière1, F. Zerbib1, D. Laharie1, F. Poullenot1

Created: Friday, 22 February 2019, 9:41 AM
P539: Patient Preferences for Inflammatory Bowel Disease Treatments: Development of a European Preference Survey using a Discrete Choice Experiment
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schoefs, E.(1)*;Vermeire, S.(2);Ferrante, M.(2);Sabino, J.(2);Verstockt, B.(2);Avedano, L.(3);De Rocchis, M.S.(3);Sajak-Szczerba, M.(3);Saldaña, R.(4);Straetemans, N.(5);Vandebroek, M.(6);Huys, I.(1);Janssens, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P539: Transcriptional changes in mucosal inflammation associated with an autoimmune protocol diet for ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Konijeti1,2, B. Molparia2,3, E. Akhtar*, X. Wang2, J. Chang4, J. Lewis5, A. Chandrasekaran6, S. Groven7, G. Oliveira2, A. Torkamani2,3

Created: Thursday, 21 February 2019, 9:14 AM
P539: Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)
Year: 2021
Source: ECCO'21 Virtual
Authors: Afzali, A.(1);Kakehi, S.(2);Lapensee, K.(2);Lukanova, R.(3);Hennessy, F.(3);Knight, H.(3);Singh, K.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P540 GB004, a novel prolyl hydroxylase inhibitor for inflammatory bowel disease, leads to gut-targeted HIF-1α pathway engagement in a multiple-dose study in healthy subjects
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Levesque1, K. Taylor Meadows2, A. Buch3, M. Flynn4, K. Peters5, A. Olson1, J. Shen1, D. Slee6, C. Van Biene7, R. Aranda1, N. Vande Casteele8, G. Opiteck1

Created: Thursday, 30 January 2020, 10:12 AM
P540: Early response as a prognostic factor for vedolizumab: A real-life experience from a single Italian tertiary centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Mezzina1*, A. Cassinotti1, S. Carmagnola1, A. Massari1, S. Grillo2, S. Landi2, G. Maconi1, S. Ardizzone1

Created: Thursday, 21 February 2019, 9:14 AM
P540: Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yamamoto T.*1, Tanaka T.2, Yokoyama T.3, Shimoyama T.1, Ikeuchi H.4, Uchino M.4, Watanabe T.2

Created: Wednesday, 20 February 2019, 10:36 AM
P540: Longitudinal Dynamics of Gut Microbiome and Metabolome After Biological Therapy in Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Ahmed, M.(1);Metwaly, A.(1);Hammoudi, N.(2);Meng, C.(3);Köhler, N.(4);Le Bourhis, L.(2);Pauling, J.(4);Kleigrewe, K.(3);Allez, M.(2);Haller, D.(1);
Created: Friday, 11 February 2022, 3:56 PM
P540: Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literature
Year: 2021
Source: ECCO'21 Virtual
Authors: Singh, H.(1);Wilson, L.(2);Pandey, A.(3);Tencer, T.(4);Kumar, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P540: The opinions and needs of patients living with refractory ulcerative proctitis, and the health care professionals who care for them; A Delphi consensus survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: RadfordBSc- MSc- PGCert- PhD student, S.(1)*;Kyriacou, M.(2);Moran, G.(3);
Created: Friday, 14 July 2023, 11:05 AM
P540: Therapeutic drug monitoring in ustekinumab: which factors affect trough levels?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Theeuwen*1, N. Provoost1, M. Koning1, A. Van der Meulen - de Jong1, D. J. A. Moes2, J. Maljaars1

Created: Friday, 22 February 2019, 9:41 AM
P541 Are we addressing the top ten research priorities in IBD?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Geldof1, J.F. LeBlanc1, L. Lucaciu2, J.P. Segal1, C.W. Lees2, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM
P541: Clinical factors associated with discontinuation of combo or monotherapy for Crohn’s disease: A sub-analysis of a prospective randomised clinical trial (DIAMOND study)
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Hisamatsu1*, T. Matsumoto2, K. Watanabe3, H. Nakase4, S. Motoya5, N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M. Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M. Watanabe17, T. Hibi18, DIAMOND study group1

Created: Thursday, 21 February 2019, 9:14 AM
P541: Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Guerra Marina, I.(1)*;Barros, F.(2);Mesonero, F.(3);de Francisco, R.(4);Cañete, F.(5,6);Benítez, J.M.(7);Sicilia, B.(8);Martín Arranz, M.D.(9);de Castro, L.(10);Carbajo, A.Y.(11);Gutiérrez, A.(6,12);Calvo, M.(13);Casanova, M.J.(6,14);González-Muñoza, C.(15);Miguel, M.(16);Alfambra, E.(6,17);Rivero, M.(18);Lucendo, A.J.(6,19);Tardillo, C.A.(20);Almela, P.(21);Bujanda, L.(6,22);Van Domselaar, M.(23);Ramos, L.(24);Fernández Sánchez, M.(25);Hinojosa, E.(26);Verdejo, C.(27);Gimenez, A.(28);Piqueras, M.(29);Rodríguez-Lago, I.(30);Manceñido, N.(31);Pérez Calle, J.L.(32);Moreno, M.D.P.(33);Delgado, P.G.(34);Antolín, B.(35);Ramírez de la Piscina, P.(36);Bermejo, F.(37);Carracedo, Á.(38);Domènech, E.(5,6);Gisbert, J.P.(6,14);
Created: Friday, 14 July 2023, 11:05 AM
P541: Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease
Year: 2022
Source: ECCO'22
Authors: Morales Bermúdez, A.I.(1);Bracho González, M.(1);Gómez Rodríguez, P.(1);Olmedo Martín, R.(1);
Created: Friday, 11 February 2022, 3:56 PM